Spring Bank Pharmaceuticals, Inc. (SBPH): Price and Financial Metrics

Spring Bank Pharmaceuticals, Inc. (SBPH): $4.84

0.00 (0.00%)

POWR Rating

Component Grades








Add SBPH to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

SBPH Price/Volume Stats

Current price $4.84 52-week high $5.22
Prev. close $1.21 52-week low $0.80
Day low $4.60 Volume 21,675
Day high $5.22 Avg. volume 177,606
50-day MA $1.30 Dividend yield N/A
200-day MA $1.37 Market Cap 83.57M

SBPH Stock Price Chart Interactive Chart >

Spring Bank Pharmaceuticals, Inc. (SBPH) Company Bio

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. The company was founded in 2002 and is based in Milford, Massachusetts

SBPH Latest News Stream

Event/Time News Detail
Loading, please wait...

SBPH Latest Social Stream

Loading social stream, please wait...

View Full SBPH Social Stream

Latest SBPH News From Around the Web

Below are the latest news stories about Spring Bank Pharmaceuticals Inc that investors may wish to consider to help them evaluate SBPH as an investment opportunity.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Spring Bank Pharmaceuticals, Inc.

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and…

PR Newswire | September 22, 2020

ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the Firm - SBPH, VAR, JCAP, GLIBA

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its…

PR Newswire | September 3, 2020

NASDAQ listing expected as F-star Therapeutics announces merger with Spring Bank Pharmaceuticals

The combined company will be headquartered at Babraham Research Campus and in Cambridge, Massachusetts.

Cambridge Independent | August 3, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Spring Bank Pharmaceuticals, Inc.

Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the proposed merger of the company with F-star Therapeutics, Limited. Spring Bank Pharmaceuticals stockholders will own approximately 38.8% of the combined company. The transaction is expected to close in late 2020.

Yahoo | July 31, 2020

Spring Bank Pharma to merge with F-Star Therapeutics in all-stock deal

In a reverse merger aimed at a Nasdaq listing, privately held F-star Therapeutics will combine with Spring Bank Pharmaceuticals ([[SBPH]] -10.1%). The new organization will do business under the F-star monikerCurrent Spring Bank and F-star equity holders will own ~38.8% and 61.2%, respectively, of the combined company.The new firm will focus...

Seeking Alpha | July 30, 2020

Read More 'SBPH' Stories Here

SBPH Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -84.43%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -84.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!